Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06602843Recruiting
Chemoimmunotherapy before and after surgery for esophageal cancer
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
HefeiAges 18–75 - NCT06603376RecruitingPhase 2
Drug combo for BRAF-mutated advanced colorectal cancer
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
ShanghaiAges 18–80 - NCT06603402RecruitingPhase 2
Low-dose radiation plus immunotherapy for esophageal cancer
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
Chengdu, SichuanAges 18–80 - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06607120Recruiting
Trial for advanced liver cancer with TACE and immunotherapy
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
Nanjing, JiangsuAges 18 years+ - NCT06607406Recruiting
Timing of radiation after surgery for head and neck cancer
This study tests whether starting radiation therapy more than 6 weeks (but within 16 weeks) after surgery is safe and effective for people with certain high-risk head and neck cancers. It could help those who had to delay radiation for recovery or other reasons.
Charlotte, North CarolinaAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06608160Recruiting
PET scan to tell if lung cancer is truly growing after immunotherapy
This trial uses a special PET scan (68Ga-grazytracer) to find out whether growth seen on scans after immunotherapy is real cancer growth or a harmless reaction called pseudoprogression. It helps doctors decide if your treatment is working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06609876Recruiting
Donafenib after ablation for recurrent liver cancer
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Beijing, None SelectedAges 18–75 - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06611072Recruiting
Boosting immune response in ovarian cancer surgery
This study examines how to improve the immune system's response during ovarian cancer surgery, potentially helping the body fight the cancer better. It compares patients with ovarian cancer to women having surgery for non-cancerous conditions.
Eindhoven, North BrabantAges 18 years+ - NCT06613269RecruitingPhase 2
PET-guided radiation therapy for clear cell kidney cancer
This trial tests whether a special PET/CT scan (68Ga-NY104) can help guide radiation therapy for people with clear cell kidney cancer. The goal is to make radiation more precise and effective for treating tumors that haven't spread too much.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+ - NCT06617169RecruitingPhase 1
Radioactive drug for solid tumors after prior study
This trial tests a new radioactive drug called MNPR-101-PCTA-177Lu for people with solid tumors who already completed a previous study (MNPR-101-D001). It aims to find the safest and most effective dose by carefully monitoring how your body handles the treatment.
North Melbourne, VictoriaAges 18 years+ - NCT06622031Recruiting
TIPS with lenvatinib and immunotherapy for advanced liver cancer
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Beijing, None SelectedAges 18–75 - NCT06623487Recruiting
PET scan to guide immunotherapy for stage III lung cancer
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06623578Recruiting
Robotic vs. open surgery for thyroid cancer that has spread
This study compares a robotic surgery method using small incisions under the armpit with standard open surgery for papillary thyroid cancer that has spread to lymph nodes on one side of the neck. It aims to see which approach is better for removing cancer and recovery.
Guangzhou, GuangdongAges 18–70 - NCT06623656RecruitingPhase 2
Pre-surgery treatment comparison for non-small cell lung cancer
This trial compares two treatment approaches before surgery for non-small cell lung cancer (NSCLC): radiation plus immunotherapy versus chemotherapy plus immunotherapy. The goal is to see which combination works better to shrink the tumor before it is removed.
New York, New YorkAges 18 years+ - NCT06625034RecruitingPhase 3
Comparing two radiation planning methods for prostate cancer
This trial tests two ways to plan radiation treatment for prostate cancer: one using a computer program (RapidPlan) and the other using human experts. The goal is to see if the computer-assisted method works as well or better.
Scottsdale, ArizonaAges 18 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80 - NCT06627738RecruitingPhase 2
Extra radiation boost for advanced lung cancer after standard treatment
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
NiceAges 18 years+ - NCT06628570Recruiting
Anal cancer screening in high-risk groups
This trial tests different screening methods to find anal cancer early in people with weakened immune systems or a history of certain precancerous conditions.
Miami, FloridaAges 30–80 - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,160 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.